Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Entrada Therapeutics, Inc. - Common Stock
(NQ:
TRDA
)
4.370
-0.410 (-8.58%)
Delayed Quote
Updated: 3:58 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Entrada Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 07, 2024
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
April 11, 2024
Via
Benzinga
Insiders Buying America's Car-Mart And 2 Other Stocks
↗
April 11, 2024
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
↗
March 22, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Recap: Entrada Therapeutics Q4 Earnings
↗
March 13, 2024
Via
Benzinga
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
↗
November 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
November 23, 2023
Via
Benzinga
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
↗
November 22, 2023
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
November 22, 2023
Via
Benzinga
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 12, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
August 01, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
June 26, 2023
Via
Benzinga
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Via
MarketBeat
Entrada Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
April 04, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
↗
April 03, 2023
Via
Benzinga
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
March 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
March 09, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
